Valeo Financial Advisors LLC Takes Position in Insulet Co. (NASDAQ:PODD)

Valeo Financial Advisors LLC bought a new stake in Insulet Co. (NASDAQ:PODD) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 795 shares of the medical instruments supplier’s stock, valued at approximately $208,000.

Several other large investors have also recently bought and sold shares of the business. Banque Pictet & Cie SA purchased a new position in Insulet in the fourth quarter valued at $287,000. Vontobel Holding Ltd. increased its holdings in Insulet by 4.3% in the fourth quarter. Vontobel Holding Ltd. now owns 2,423 shares of the medical instruments supplier’s stock valued at $633,000 after buying an additional 100 shares during the last quarter. Bogart Wealth LLC purchased a new position in Insulet in the fourth quarter valued at $6,170,000. Asset Management One Co. Ltd. increased its holdings in Insulet by 2.3% in the fourth quarter. Asset Management One Co. Ltd. now owns 26,766 shares of the medical instruments supplier’s stock valued at $7,096,000 after buying an additional 605 shares during the last quarter. Finally, Certuity LLC purchased a new position in Insulet in the fourth quarter valued at $245,000.

Insulet Stock Performance

NASDAQ PODD opened at $280.71 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The business’s 50-day moving average price is $272.17 and its 200 day moving average price is $245.91. The firm has a market cap of $19.69 billion, a P/E ratio of 48.07, a P/E/G ratio of 3.61 and a beta of 1.23.

Analyst Ratings Changes

Several research firms recently commented on PODD. Morgan Stanley increased their target price on Insulet from $234.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, November 11th. Wells Fargo & Company raised their price objective on Insulet from $290.00 to $305.00 and gave the stock an “overweight” rating in a report on Wednesday, December 11th. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 price objective on the stock. TD Cowen raised their price objective on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Finally, JPMorgan Chase & Co. raised their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a report on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $277.13.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CAO Lauren Budden sold 915 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total transaction of $252,192.30. Following the completion of the sale, the chief accounting officer now owns 5,733 shares of the company’s stock, valued at approximately $1,580,129.46. The trade was a 13.76 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.